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Abstract:Only the kinase domain of ERBB4 has been analyzed in East
Asian populations, but a recent large-scale mutation analysis has indi-
cated a higher incidence of mutations in the extracellular domain.
Mutations in the extracellular and kinase domains of ERBB4 were
examined by direct sequencing in 72 patients with primary lung cancer
and 8 cell lines. In addition, ERBB4 expression was determined in 60
patients by quantitative real-time polymerase chain reaction. We inves-
tigated the relationship between ERBB4 expression and clinicopatho-
logic characteristics including prognosis. One patient possessed Q793Q
polymorphism in the kinase domain. However, we detected no muta-
tions in extracellular or kinase domains of ERBB4. There was no
significant difference in the clinicopathologic characteristics including
prognosis of patients with high or low expression of ERBB4. The
clinical significance of ERBB4 in lung cancers is negligible.
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The ERBB family of tyrosine kinase receptors consists of fourmembers: epidermal growth factor receptor (EGFR),
ERBB2, ERBB3, and ERBB4.1 According to the NCBI database,
the sequences of the kinase domains of EGFR and ERBB4 are
79% identical, and EGFR and ERBB4 have common ligands:
heparin-binding epidermal growth factor, betacellulin, and epi-
regulin.1 EGFR mutation has been revealed to play an important
role in non-small cell lung cancer (NSCLC).
Two mutation analyses of the ERBB4 kinase domain in
East Asian patients with NSCLC have been reported: 5 of 217
(2.3%) in Korean patients2 and none of 105 in Japanese pa-
tients.3 Conversely, a large-scale mutation analysis in 188 pa-
tients with lung adenocarcinoma detected nine ERBB4 muta-
tions: two in the kinase domain, one in the transmembrane
domain, and six in the extracellular domains (Figure 1A).4
The extracellular domains of the ERBB family are con-
sisted of four distinct protein domains. There are two homolo-
gous large (L) domains and two cysteine-rich (CR) domains,
which occur in the order L1–CR1–L2–CR2 (Figure 1A).5 The
L1 and L2 domains form the ligand binding pocket and the CR1
and CR2 domains are deeply involved in receptor dimerization.5
Mutations in the ERBB4 gene are more frequently present in the
extracellular domain, especially the CR1 domain, than in the
kinase domain.4 However, only the kinase domain has been
analyzed in East Asian populations.2,3 We considered that anal-
ysis of mutations in the extracellular domains and the kinase
domain of ERBB4 would be of value.
In this study, we searched for mutations in the CR1
domain and kinase domain of ERBB4. We also analyzed ERBB4
mRNA expression by real-time polymerase chain reaction and
examined the relationship between the expression and clinico-
pathologic characteristics including prognosis.
PATIENTS AND METHODS
Cell Lines
Eight lung cancer cell lines were available. These com-
prised six adenocarcinomas (NCI-H23, NCI-H358, NCI-H3255,
HCC78, A549, and ACC-LC-319), one adenosquamous cell
carcinoma (NCI-H596), and one large cell carcinoma (ACC-
LC-91). ACC-LC-319 and ACC-LC-91 were established in our
institution. A549 and NCI-H596 were purchased from the
American Type Culture Collection (Manassas, VA). The others
were gifts from Dr. Adi F. Gazdar.
Patients
We studied 72 Japanese patients with lung cancer who
underwent pulmonary resection at our institution. Tumor sam-
ples were rapidly frozen, and total RNA were extracted and
genomic DNA was extracted from the blood sample using the
Gene Tapping by Liquid Extraction kit (TAKARA BIO Inc.,
Otsu, Japan) after obtaining appropriate approval from the re-
view board and written informed consent from the patients. The
clinicopathologic characteristics of the patients were as follows:
44 were men and 28 were women, and the median age was 67
years at diagnosis (range, 38–85 years). Thirty-nine patients had
pathologic stage I disease, 7 had stage II, 23 had stage III, and 3
had stage IV (TNM Classification of Malignant tumor, 6th
Edition). There were 55 adenocarcinomas, 10 squamous cell
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carcinomas, 1 adenosquamous cell carcinomas, 5 large cell
carcinomas, and 1 small cell carcinoma. Twenty-four patients
had never smoked, and 48 were current or former smokers.
Analysis of ERBB4 Mutations
The ERBB4 extracellular region and kinase domain,
which was divided into C-terminal side (KD1) and N-terminal
side (KD2; Figure 1A), were analyzed for mutations. By using
total RNA or genomic DNA, ERBB4 was analyzed by direct.
Primer sequences were as follows: extracellular region, 5-TCCTT-
TGTTATGCAGACACCAT-3 and 5-TTGTAAGGGTCCCC-
ATGAATAC-3; KD1, 5-GGTGGAACCATTAACTCCCAGT-
3 and 5-CAATGCTGATGGAGGAAAGATG-3; and KD2,
5-CAATGCTGATGGAGGAAAGATG-3 and 5-TGATCG-
TATGAAGCTTCCCAG-3.
Analysis of ERBB4 Expression
Total RNA from 60 patients and 2 normal lung tissue
samples were reverse transcribed using the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems, Foster
City, CA). We analyzed ERBB4 expressions according to the
protocol of the TaqMan Gene Expression assay, using 18S
rRNA as the internal reference gene. The primer IDs for ERBB4
and 18S rRNA were Hs00171783_m1 and Hs99999901_s1
(Applied Biosystems), respectively. The 60 patients were di-
vided into 2 groups on the basis of the average ERBB4 expres-
sion value of 2 normal lung tissue samples.
Statistical Analysis
For comparison of proportions, a 2 test or Fisher’s exact
test was applied. For quantitative variables, Student t test was
used. Disease-free survival (DFS) was measured from the date
of first operation until the date of radiologic recurrence or death.
Overall survival (OS) was measured from the date of first
operation until the date of death. The Kaplan–Meier method was
used to estimate the probability of survival as a function of time,
and survival differences were analyzed by the log-rank test. We
defined the significance level at p  0.05.
RESULTS
In the ERBB4 mutation analysis, one patient with adeno-
carcinoma had a c.2379GA synonymous genetic change re-
sulting in Q793Q in the ERBB4 kinase domain (exon 20). The
synonymous change was confirmed as a polymorphism by DNA
sequencing a matched blood sample (Figure 1B). However,
somatic mutation of ERBB4 was not detected in this study.
The average ERBB4 expression level was not signifi-
cantly different between tumor samples and normal lung
tissue samples (p  0.384). The high- and low-expression
groups were 27% (16 of 60 patients) and 73% (44 of 60
patients), respectively. The two groups were compared for
clinicopathologic characteristics (Table 1), but we did not
identify any significant difference. In the survival analysis,
the median DFS and OS time was not significantly different
between the patients with high and low ERBB4 expression
(Figures 1C, D).
DISCUSSION
We have previously analyzed EGFR, KRAS, MET, and
ERBB2 mutations and MET amplification, which are mutually
FIGURE 1. A, ERBB4 mutations
from the previous reports of Ding et
al.4 (arrow) and Soung et al.2 (dot-
ted arrow) and the Q793Q poly-
morphism identified in this study
(thick arrow) are illustrated. ERBB4
consists of four extracellular do-
mains, a transmembrane domain
(TM), and a kinase domain. The ki-
nase domain is divided into two re-
gions. L1, 2: large domain 1, 2 CR1:
2; CR domain 1, 2. B, Sequencing
chromatograms for the synonymous
mutation identified in exon 20 of
ERBB4 in the tumor and blood from
the same patient. The nucleotide
change was c.2379GA, which did
not lead to substitution of glu-
tamine at position 793. C and D,
Kaplan–Meier estimates of disease-
free survival and overall survival in
patients with high and low ERBB4
expression. The median disease-free
survival time and overall survival
time were not significantly different
among the two groups.
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exclusive, in lung cancers.6,7 The aims of this study were to
identify mutations of the ERBB4 extracellular and kinase do-
mains in lung cancers and to confirm their mutual exclusivity
with mutations in the above genes. Recently, activating point
mutations at the EGFR extracellular domains were found in
12.9% of glioblastoma.8 Mutations of the ERBB4 extracellular
domain also have been reported in NSCLC.4 We considered that
there was need for analysis of mutations of the ERBB4 extra-
cellular domain in East Asian patients with lung cancer. In this
mutation analysis, only a Q793Q polymorphism was detected in
the ERBB4 kinase domain. The ERBB4 polymorphism was
analogous to the Q787Q polymorphism of EGFR. In East Asia,
two mutation analyses of ERBB4 have been reported.2,3 Consid-
ering those together with this study, 5 of 394 patients with lung
cancer (1.3%) harbored ERBB4 mutations, all of which were
present in the ERBB4 kinase domain.
Gene amplification and expression of the ERBB family
have been reported in lung cancer. EGFR gene amplifications
are frequently observed in squamous cell carcinoma with poor
prognosis.9,10 Synchronous protein overexpression of EGFR and
ERBB2 significantly predicted increased recurrence risk and
decreased survival.11 In ERBB4 expression assays of lung can-
cers, the expression levels are remarkably lower than those of
other members of the ERBB family, and there is no relationship
between ERBB4 expression and metastasis.12 Conversely, Starr
et al.13 reported that the proliferation of the ERBB4-transfected
human adenocarcinoma cell line H1299 was 2-fold higher than
that of the parental cells, and in mice injected with the ERBB4-
transfected cells, the tumors were larger,13 suggesting that
ERBB4 is associated with metastasis and inferior survival.13
As indicated earlier, opinions vary concerning the rela-
tionship of ERBB4 expression with metastasis and prognosis in
lung cancers. In this study, the patients with regional lymph node
or distant metastasis at diagnosis made up 40% (6 of 16 patients)
of the ERBB4 high-expression group and 44% (20 of 44 pa-
tients) of the ERBB4 low-expression group (p  0.582). The
DFS and OS were not significantly different between the high-
and low-expression groups. There was no significant relation-
ship between ERBB4 expression and metastasis or prognosis,
and we did not detect a significant relationship between ERBB4
expression and any clinicopathologic factors.
In conclusion, mutation of the ERBB4 kinase domain
and CR1 domain were not detected. High ERBB4 expression
was infrequent in Japanese patients with lung cancer, and the
clinical significance of ERBB4 was negligible.
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TABLE 1. Clinicopathologic Data for 60 Patients with Lung
Cancer
Characteristic
ERBB4 Expression (%)
p
High
(n  16)
Low
(n  44)
Age (yr)
67 7 (43.8) 23 (52.3) 0.559
67 9 (56.2) 21 (47.7)
Sex
Male 8 (50.0) 31 (70.5) 0.142
Female 8 (50.0) 13 (29.5)
Pathologic stage
I, II 13 (81.3) 25 (56.8) 0.130
III, IV 3 (18.7) 19 (43.2)
Smoking
Never 6 (37.5) 12 (27.3) 0.445
Current or former 10 (62.5) 32 (72.7)
Tumor size (cm)
3 6 (43.8) 28 (63.6) 0.071
3 10 (56.2) 16 (36.4)
Histology
Adenocarcinoma 11 (68.9) 32 (72.7) 0.763
Nonadenocarcinoma 5 (31.1) 12 (27.3)
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